Amgen Q1 call signals launch well underway for Repatha in Japan

Bob Bradway
Amgen Chairman and CEO Bob Bradway

Repatha sales kicked off in Japan late last month with Amgen ($AMGN) not shy in raising sales expectations on the first quarter earnings call after reimbursement was set.

Tony Hooper, head of global commercial operations, said on the April 28 earnings call that the first PCSK9 inhibitor therapy to reach Japan was up and running with partner Tokyo-based Astellas Pharma under the local unit, Amgen Astellas BioPharma.

"In Japan we have now received pricing approval and launch activities with our partner Astellas are well underway," Hooper said.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

Earlier in April, Japan's National Health Insurance program set a price of ¥22,948 ($205.37) for the treatment--setting the stage for potential peak sales of ¥49.2 billion ($440 million) at the end of the decade with 69,000 patients seen on the therapy, according to data from the Central Social Insurance Medical Council (Chuikyo).

Cooper went on to say, in response to a question from analyst Jeff Chen of Cowen and Company, that the reimbursement in Japan offers an overall set price level compared to launched in Europe.

"When you come in with larger expanded patient population groups, there's a chance in Europe you have to go back into a country-by-country negotiation," Hooper said. "In Japan, historically, that hasn't happened as much and the pricing we received in Japan seems to be a longer play-through from pricing."

Still, Japan's Ministry of Health, Labor and Welfare has cautioned doctors to limit prescriptions to high-risk cardiovascular patients that do not respond to statins.

- here's the release from Amgen

Read more on

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

Kinase inhibitors to treat cancer have driven nearly $100 billion in deals since 2010, a trend that's likely to grow, SVB Leerink analysts predict.